Subscribe to an RSS Feed Reports:
Amylin Pharmaceuticals, Inc. (AMLN):
|
Don't see the Scenario report you want?
- Merger and Acquisition Scenario for Novo Nordisk A/S (ADR) (NVO) and Amylin Pharmaceuticals, Inc. (AMLN) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Sep 04, 2010 - HTML - View Report »
- FDA Approval Decisions Report for Apr, 2009 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Apr 01, 2009 - PDF - $125.00 - Add to Cart »
- FDA Approval Decisions Report for Dec, 2006 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Dec 01, 2006 - PDF - View Report »
- FDA Approval Decisions Report for Dec, 2008 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Dec 01, 2008 - PDF - $125.00 - Add to Cart »
- FDA Approval Decisions Report for Feb, 2007 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Feb 01, 2007 - PDF - View Report »
- FDA Approval Decisions Report for Feb, 2009 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Feb 01, 2009 - PDF - $125.00 - Add to Cart »
- FDA Approval Decisions Report for Jan, 2007 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Jan 01, 2007 - PDF - View Report »
- FDA Approval Decisions Report for Jan, 2009 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Jan 01, 2009 - PDF - $125.00 - Add to Cart »
- FDA Approval Decisions Report for Mar, 2009 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Mar 01, 2009 - PDF - $125.00 - Add to Cart »
- FDA Approval Decisions Report for Nov, 2008 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Nov 01, 2008 - PDF - $125.00 - Add to Cart »
- FDA Approval Decisions Report for Oct, 2008 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Oct 01, 2008 - PDF - $125.00 - Add to Cart »
- Competitors by Product for Amylin Pharmaceuticals, Inc. (AMLN) Exact product by product comparables to each of a company's competitors which trade on a major US exchange. Revere - Sep 04, 2010 - HTML - $75.00 - Add to Cart »
- Drug/Medical Device for Amylin Pharmaceuticals, Inc. (AMLN) The most complete and accurate coverage of a company's FDA approved products and pipeline candidates. Revere - Sep 04, 2010 - PDF - $70.00 - Add to Cart »
- Merger and Acquisition Scenario for Novo Nordisk A/S (ADR) (NVO) and Amylin Pharmaceuticals, Inc. (AMLN) See what a hypothetical merger or acquisition between two firms would look like, with a particular focus on overlapping and complementary product lines and key business relationships. Revere - Sep 04, 2010 - HTML - View Report »
- FDA Approval Decisions Report for April, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Apr 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for August, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Aug 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for February, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Feb 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for January, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Jan 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for March, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Mar 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for September, 2010 The Revere FDA Approval Decision Report provides one of the most comprehensive and accurate event calendars for PDUFA dates-expected FDA approval dates for filed drugs. In particular, this report identifies Biotech/Pharmaceutical companies with expected FDA approvals in the next 3 months and reviews all FDA approval decisions in the current month. Revere - Sep 01, 2010 - ZIP - $125.00 - Add to Cart »